Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.10M | -5.05M | -5.77M | -7.23M | -8.23M |
| Total Depreciation and Amortization | 393.00K | 390.00K | 378.00K | 374.00K | 364.00K |
| Total Amortization of Deferred Charges | 4.00K | 9.00K | 16.00K | 16.00K | -279.00K |
| Total Other Non-Cash Items | 527.00K | 297.00K | 656.00K | 1.09M | -30.00K |
| Change in Net Operating Assets | -2.25M | -588.00K | -777.00K | 1.92M | 2.99M |
| Cash from Operations | -5.42M | -4.95M | -5.49M | -3.83M | -5.19M |
| Capital Expenditure | -5.00K | -6.00K | 0.00 | -5.00K | -70.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 35.00K |
| Cash from Investing | -5.00K | -6.00K | 0.00 | -5.00K | -35.00K |
| Total Debt Issued | 0.00 | 600.00K | 0.00 | 3.20M | 0.00 |
| Total Debt Repaid | -19.00K | -18.00K | -1.82M | -23.00K | -2.30M |
| Issuance of Common Stock | 13.63M | 3.74M | 5.51M | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -502.00K | 1.73M | 1.51M | -164.00K | -660.00K |
| Cash from Financing | 13.11M | 6.05M | 5.20M | 3.01M | -2.96M |
| Foreign Exchange rate Adjustments | 16.00K | -33.00K | -13.00K | 17.00K | -19.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.69M | 1.06M | -307.00K | -806.00K | -8.20M |